282,801 video views
obr: Videos
01:16
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic hormone-sensiti​ve prostate cancer.
by:obr | 1286 views
01:27
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).
by:obr | 513 views
01:21
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.
by:obr | 330 views
01:20
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma (RCC) patients.
by:obr | 302 views
02:37
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell cancer and urothelial cancer.
by:obr | 240 views
02:12
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE trial in metastatic, untreated renal cell carcinoma.
by:obr | 130 views
02:48
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atriu​m Health, UNC Chapel Hill School of Medicine shares the data in smoldering multiple myeloma (MM) presented at ASCO 2019.
by:obr | 188 views
01:53
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atriu​m Health, UNC Chapel Hill School of Medicine provides outcomes from the MAIA study that compares daratumumab + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in multiple myeloma elderly patients.
by:obr | 281 views
01:38
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atriu​m Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.
by:obr | 161 views
01:55
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains the results of the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.
by:obr | 205 views
dsfsd